Archive for June, 2009

Alternative, complementary, natural, and homeopathic.

Link:  http://www.boston.com/news/health/articles/2009/06/29/the_risks_and_rewards_of_all_natural_supplements/

Boston Globe, 6/29/09

The allure is undeniable. Stroll into a store, pluck a remedy branded “all-natural’’ from the shelf, and pay the price tattooed on the bottle. No insurance card, no prescription, no doctor appointment required.

But there’s also no guarantee that what you’re buying will cure your cold, silence your arthritis, or calm your nerves. And it might even spark serious side effects – especially if an otherwise innocuous herb is taken with a powerful prescription pill, producing a toxic brew.

This month, an over-the-counter cold treatment called Zicam landed in the cross hairs of the US Food and Drug Administration after the agency received more than 100 reports of users losing their ability to smell – sometimes briefly, sometimes permanently. The FDA’s advice: Stop using Zicam sprays and gels. Immediately. It was the latest cautionary tale about products that, in the main, fly under the radar of regulatory agencies whose main job is approving and monitoring prescription medications.

Americans spend billions of dollars annually on pills, herbs, and other medical products known variously as alternative, complementary, natural, and homeopathic. And the users – including some traditionally trained physicians – swear by them, even if federal drug regulators don’t. Manufacturers argue that many of the products – especially herbs – have survived the crucible of time, used through the ages without complaint. Consumer advocates counter that longevity is no substitute for gold-standard scientific evidence.

This much is clear: More than five years after the FDA banished an herbal weight-loss compound called ephedra that was blamed for 155 deaths, the love affair with supplements blazes hotter than ever. Never has it been more important for patients and doctors alike to understand the potential promise and peril carried in the amber bottles of hope stocked on bulging shelves.

“You’ll find one person who says this is the next best thing since sliced bread, and somebody else who says this will kill you. But, really, the truth is somewhere between,’’ said Candy Tsourounis, a professor of clinical pharmacy at the University of California-San Francisco. “So how does a consumer get the truth from these two polar opposites? It’s going to the right provider, asking the right questions, being informed.’’

When Dr. Benjamin Kruskal encounters patients for the first time in his Somerville office, he lets them know he harbors no hostility toward alternative medicine.

“The biggest thing I communicate to people is caution and looking hard for evidence about safety – above all else, safety first,’’ said Kruskal, who practices at Harvard Vanguard Medical Associates. “And I do encourage people to tell me what they’re using. A lot of people say, ‘I’m taking vitamins, that doesn’t count as a medicine.’ But if they’re taking 3 grams of vitamin C, it sure does count as medicine.’’

It’s important for physicians to know whether patients are taking herbs or other products that can react powerfully with prescription medications, sometimes amplifying the effect of those drugs, sometimes muting it.

For instance, the herb St. John’s wort, which has been shown in some scientific studies to alleviate depression, can impair the liver’s ability to process certain drugs. That’s why HIV patients taking medication called protease inhibitors are urged not to use the herb. There’s also evidence that St. John’s wort can make birth control pills less effective.

Patients who take the blood- thinning drug Coumadin – sometimes prescribed after a heart attack or stroke – are told to be especially forthright with their doctors when discussing supplements they take, because some over-the-counter products have been shown to alter the medication’s function.

Herbs and homeopathic products, the class that includes Zicam, do not have to undergo elaborate, expensive scientific studies proving they work before they can be marketed – unlike prescription medications. Nor do they require the FDA’s approval, although manufacturers must promptly alert regulators if they receive reports of serious side effects linked to their products.

(Of course, as scandals with some prescription drugs have so clearly demonstrated – think Vioxx – the FDA’s approval process is hardly foolproof.)

Companies that make supplements and herbs, much like food processors, are required to hew to good manufacturing practices. But those rules are no assurance that the ginkgo you buy in one shop is the same strength as the ginkgo peddled down the street.

“One thing we can say for sure is if consumers are contemplating using a medication, they should familiarize themselves quite well with what’s on the label,’’ said Dr. Charles Lee, an FDA medical officer.

Evidence that supplements truly help is spotty – and, sometimes, bewilderingly mixed.

Consider the widely used herb echinacea, heralded for its purported ability to dampen, or even prevent, respiratory infections. Scientists at the National Center for Complementary and Alternative Medicine – it has a trove of information at www.nccam.nih.gov – declare that when it comes to preventing colds or the flu, echinacea is a bust.

The findings are more equivocal regarding the herb’s ability to treat a cold once it has already settled in. While two studies funded by the federal agency concluded there was no evidence echinacea can ease a cold, other studies have shown it may indeed help.

“The issue is this,’’ said Dr. Sidney Wolfe, acting president of Public Citizen, a leading consumer advocacy group whose research has seared prescription products as well as alternative supplements: “Anything that is supposed to affect the human body should have scientific evidence that it affects the human body in a good way and that it is safe.’’

Michael McGuffin, president of the American Herbal Products Association, a trade alliance, has an answer for Wolfe: Pay attention to history.

“If I’m marketing an herbal ingredient that’s used for a purpose that’s known and consistent for hundreds of years . . . do I need’’ a gold-standard scientific trial, McGuffin asked. “I don’t think so. I have respect for these uses that have been recorded for centuries. I just don’t see that there’s a need for a new scientific model to confirm what we already know from experience.’’

Sometimes, deciding whether to use a supplement for a relatively minor ailment comes down to an exquisite balancing of benefit and risk.

Such was the case with Dr. Rick McKinney, who melds mainstream health practices with the less conventional approaches favored by some of his patients. A few years back, the fog of a cold descended upon him.

He could have just soldiered on, enduring the drip, drip, drip. But a buddy had touted Zicam. “By God, it worked – it was a huge reduction in the nuisance symptoms of the common cold,’’ said McKinney, a UC-San Francisco physician who acknowledges his was a scientifically irrelevant “study of one.’’

It proved to be the only time he used the spray. McKinney decided to dig a little and discovered that some Zicam users reported losing their sense of smell after squirting the zinc-laced compound up their nostrils.

“I wasn’t willing to take the chance,’’ McKinney said. “If this was a chance to cure me of cancer, sign me up. But this was a chance I was taking to avoid nuisance-level symptoms and not something that was going to make me live any longer – even if it worked well.’’

Stephen Smith can be reached at stsmith@globe.com.

© Copyright 2009 Globe Newspaper Company.

Boomerang Re-Admissions

Link:  http://www.washingtonpost.com/wp-dyn/content/article/2009/06/29/AR2009062903134.html

Washington Post, 6/29/09

Doctors call them frequent fliers.

They are the patients who leave the hospital, only to boomerang back days or weeks later. They have become a front-burner challenge not only for hospitals and doctors but also for those trying to rein in rising costs.

Typically elderly and suffering from the chronic diseases that account for 75 percent of health-care spending, their experiences of being readmitted time and again reflect many of the deficiencies in a fragmented, poorly coordinated health system geared toward acute care.

Take Margaret White. With better management of her congestive heart failure, she might have avoided being rehospitalized this spring for five days. She’s back home again now, doing well, with help from a new monitoring program at Inova Mount Vernon Hospital in Alexandria.

There are many reasons for readmissions, including high rates of medical errors and hospital-acquired infections; lack of communication between doctors who care for patients in the hospital and their regular physicians; trouble getting a prompt doctor’s appointment after discharge; missed referrals for home health care; and poor coordination and medication management during transitions from hospital to home or nursing home.

“Transitions are just so dangerous. Every time you move a patient from one setting or facility to another, you have to ask, ‘Is something going to go wrong?’ ” said Joan Teno, a geriatrician at Brown University Medical School, who has often treated her patients in nursing homes for conditions that otherwise would propel them back to the hospital. Teno said the ways nursing homes are paid mean it’s often easier for them to let the hospitals take care of sick patients.

Experts don’t agree on how many readmissions are avoidable. Dozens of promising initiatives designed to cut down on them are underway. But many experts say sweeping changes are needed in how health care is delivered and how hospitals and doctors are paid — sensitive issues that confront Congress and the medical industry in the debate on overhauling the health system.

President Obama and health reformers in Congress are looking at many ways to reward quality and emphasize prevention and coordination. Right now, hospitals — such as Inova Mount Vernon — that do a better job of preventing readmissions sometimes end up losing money because the health-care system doesn’t pay for the extra work they do. Some health reform proposals would change the way hospitals are paid, so that stopping readmissions becomes good business.

One idea is to bundle the payments to hospitals, doctors and perhaps nursing homes or rehabilitation centers, to cover both the hospitalization and those first critical weeks after discharge.

Another proposal is to have Medicare penalize hospitals with high readmission rates for eight common chronic diseases. Members of both parties have been looking at ways of paying primary care doctors more to help patients manage their chronic diseases and avoid trips to the hospital every few weeks or months.

Both doctors groups and the American Hospital Association have agreed that it’s time to address readmissions. The association, however, prefers to start with pilot programs to test new payment systems rather than implementing an across-the-board new approach. The AHA also says hospitals should not be held responsible for problems that patients encounter when they’re outside the hospitals’ control.

Readmission costs are staggering. One of five Medicare hospital patients returns to the hospital within 30 days — at a cost to Medicare of $12 billion to $15 billion a year — and by 90 days the rate rises to one of three, according to an analysis of 2007 data by Stephen Jencks. Within a year, two out of three are back in the hospital — or dead. Jencks consults on this issue for the independent Massachusetts-based Institute for Healthcare Improvement.

For the population as a whole, including patients too young for Medicare, the readmission rate is 14 to 19 percent for the first 30 days, said Jencks.

One tactic used by Inova Mount Vernon is to change the way it deals with some discharged patients.

For example, the hospital began its HeartLink program in November, after Honora Fowler, a nurse, and Lynne Weir, a physical therapist who specializes in cardiac rehabilitation, brainstormed about how to help their congestive heart failure patients take better care of themselves.

Patients monitor themselves daily and call a toll-free telephone line to answer some simple questions about weight gain, swelling and breathing difficulties.

Fowler reviews the answers to see whom she needs to call, whom she needs to keep an eye on for a day or two, who needs their medications adjusted and who better get in to see a doctor right away. Occasionally, with a patient with advanced disease, she calls a case worker or doctor to suggest it’s time to have a gentle conversation about palliative care or hospice.

White’s first hospitalization for her heart disease was last September, before HeartLink was up and running. When she returned this spring, her cardiologist talked to her about HeartLink.

“I hadn’t been paying attention to the fluids. In fact, when I gained the weight, I didn’t realize it was all fluid, I thought it was good, that I was regaining the weight I had lost” during treatment a year earlier for breast cancer, said White, 59. Now she weighs herself daily, checks her feet for swelling, pays attention to changes in her breathing, and calls it all in to HeartLink, which Inova offers at no charge.

After months of barely getting out of bed, White has started a small summer vegetable garden on her balcony in Alexandria.

“We catch problems faster,” Fowler said. Because the patients and their families trust her, she can find out what went wrong and how to stop it. Sometimes it’s as simple as persuading a heart failure patient that it’s not okay to splurge occasionally on a bacon double-cheeseburger.

Some doctors are skeptical of this new stress on avoidable hospitalizations. At an American Medical Association meeting in Washington this year, some questioned whether they could do much to reduce hospitalizations. Cases can be very complicated, they said; patients don’t always follow directions.

HeartLink is new and small, and the results are anecdotal and preliminary. But other hospitals and doctors say they’re proving that innovative approaches can cut readmissions while providing higher-quality care at lower cost.

At Saint Luke’s Hospital in Cedar Rapids, Iowa, nurse Peggy Bradke and her team use a simple “Teach Back” system to make sure that patients or a family member truly understand all the medications and treatments needed at home.

Instead of going home with a sheaf of incomprehensible discharge instructions, patients leave St. Luke’s with simple information, a refrigerator magnet with danger signs, a phone number they can call day or night and an appointment with their doctor, preferably within three to five days. Making that appointment is essential. Jencks’s research has shown that half the patients who are readmitted within a month hadn’t seen a doctor after leaving the hospital.

Then, even though it’s not paid for by Medicare or other insurance, St. Luke’s sends a nurse to the patient’s home at no charge 24 to 48 hours after discharge, and follows up later with a phone call.

“We’ve had some great catches,” said Bradke. “We find a shoebox full of meds that is completely different from what we thought they were taking in the hospital. Or we find that one of the hospital prescriptions wasn’t filled or [was] not delivered.”

Bradke’s team intervened when Frederick Peterson, 72, a “frequent flier” who has lost track of how many times he has been admitted, returned to the hospital yet again in January. Among his many health problems, Peterson has had congestive heart failure for a decade, which he has not always controlled well. Sometimes he has gone back into the hospital just days after being discharged.

“A nurse came home and went over all my medications. She even went over the labels in our canned food,” Peterson said. “I knew salt was bad, but I still used it. But this nurse explained it more thoroughly and now we don’t use salt.”

St. Luke’s three-year-old program has cut the hospital’s 30-day readmission rate for congestive heart failure patients in half, from 12 to 6 percent. The goal is to bring it to 4 percent. Even when patients do return to the hospital, they tend to have shorter stays and less severe illness.

Pat Rutherford, a vice president at the Institute for Healthcare Improvement, has been working with hospitals across the country that want to see less of their frequent fliers.

“There are a lot of innovations out there, and we have growing evidence that we can improve this for the patient, to make their experience better and make sure they have a better handoff to a home or community setting,” she said.

“How many hospitals are ready to step up to the plate? That’s to be determined,” she added. “But more and more are becoming aware that in terms of quality and cost, this could be a huge home run if we do it right.”

This story was produced through a collaboration between The Post and Kaiser Health News. KHN is a service of the Kaiser Family Foundation, a nonpartisan health-care-policy research organization unaffiliated with Kaiser Permanente. Comments: health@washpost.com.

 

 

OMNI Postings of 6/30/09

Bernie Madoff:  What’s that?

Guard:  That’s your new home, 983867.

Bernie:  It’s only one room!

Guard:  But it’s very efficient.  You can eat, read, sleep, take a crap without exerting yourself.

Bernie:  You mean that’s my bed?

Guard:  Yep.

Bernie:  Sheets?

Guard:  Yep.

Bernie:  How many threads per square inch?

Guard:  Two.

Bernie:  But I have tender skin!

Guard:  Yeah, a couple of the inmates noticed.  I wouldn’t bend over for the soap.

Bernie:  And that?

Guard:  What?

Bernie:  That contraption with the hole.

Guard:  Your toilet.

Bernie:  You mean that’s where I’m supposed to do number 1 and 2?

Guard:  And 3 and 4 for all I care.

Bernie:  But there’s no seat.

Guard:  Make believe.

Bernie:  But the toilet paper has wood splinters in it!

Guard:  That’s a present from the warden.  He lost $3.6 million from your Ponzi scheme.

But I digress……

It’s official.  The FDA confirmed that they found E. coli in the cookie dough.  They also found Michael Jackson’s other glove!
http://omniphysicians.com/2009/06/30/e-coli-cookie-dough/ 

The big news today is that  walkers and canes can be dangerous.  According to CDC, from 2001 to 2006, a total of more than 47,000 oldsters each year came to the ED for injuries from falls that involved walkers and canes.  That’s something Michael Jackson won’t have to worry about anymore.
http://omniphysicians.com/2009/06/29/walkers-and-canes-can-be-hazardous-to-ones-health/

Here’s the latest map of the world showing where all the H1N1 cases are located.  It’s ironic, but apart from Antarctica, the one other continnt that seems to be largely protected from the pandemic is Africa.  Meanwhile, the North American continent looks like a cesspool of swine flu.
http://omniphysicians.com/2009/06/29/who-h1n1-map-of-the-world/

This study published in Pediatrics looked at acute sinusitis in kids and the use of antibiotics.  It was a randomized, double-blind, placebo-controlled study, but the study population included subjects who were thought to have acute bacterial sinusitis based on clinical findings.  Children receiving the antibiotic were more likely to be cured (50% vs 14%) and less likely to have treatment failure (14% vs 68%) than children receiving the placebo.  And the best antibiotic was Augmentin.
http://omniphysicians.com/2009/06/29/amoxicillinclavulanate-potassium-in-the-treatment-of-acute-bacterial-sinusitis-in-children/

Paul R

E. coli & Cookie Dough

For Immediate Release: June 29, 2009

Media Inquiries: Stephanie Kwisnek, 301-796-4737, Stephanie.Kwisnek@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA

FDA CONFIRMS E. COLI O157:H7 IN PREPACKAGED NESTLÉ TOLL HOUSE REFRIGERATED COOKIE DOUGH

Today, the U.S. Food and Drug Administration announced that it has found E. coli O157:H7 (a bacterium that can cause serious food borne illness) in a sample of prepackaged Nestlé Toll House refrigerated cookie dough currently under recall by the manufacturer and marketer, Nestlé USA.  The contaminated sample was collected at Nestlé’s facility in Danville, Va. on June 25, 2009. 

On June 19, the FDA and the U.S. Centers for Disease Control and Prevention warned consumers not to eat any varieties of prepackaged Nestlé Toll House refrigerated cookie dough due to the risk of contamination with E. coli O157:H7.  The warning was based on an epidemiological study conducted by the CDC and several state and local health departments. As of Thursday, June 25, the CDC reports that 69 persons from 29 states have been infected with the outbreak strain. Thirty-four persons have been hospitalized, nine with a severe complication called hemolytic uremic syndrome. No one has died.

Further laboratory testing is needed to conclusively link the E. coli strain found in the product to the same strain that is causing the outbreak.

Nestlé USA has fully cooperated with the FDA and CDC investigation and has recalled all of its prepackaged Nestlé Toll House refrigerated cookie dough products.

For answers to consumer questions about this recall and warning, go to: http://www.fda.gov/Food/ResourcesForYou/Consumers/ucm168346.htm.

For more information about E. coli, visit the CDC Web site at: http://www.cdc.gov/ecoli/.

Consumers who have additional questions about these products should contact Nestlé USA consumer services at 1-800-559-5025 and/or visit its Web site at www.verybestbaking.com.exit icon

Amoxicillin/Clavulanate Potassium in the Treatment of Acute Bacterial Sinusitis in Children

Effectiveness of Amoxicillin/Clavulanate Potassium in the Treatment of
Acute Bacterial Sinusitis in Children
Ellen R. Wald, David Nash, and Jens Eickhoff
Pediatrics 2009;124 9-15

OBJECTIVE: The role of antibiotic therapy in managing acute bacterial sinusitis (ABS) in children is controversial. The purpose of this study was to determine the effectiveness of high-dose amoxicillin/potassium clavulanate in the treatment of children diagnosed with ABS.

METHODS: This was a randomized, double-blind, placebo-controlled study. Children 1 to 10 years of age with a clinical presentation compatible with ABS were eligible for participation. Patients were stratified according to age (<6 or ≥6 years) and clinical severity and randomly assigned to receive either amoxicillin (90 mg/kg) with potassium clavulanate (6.4 mg/kg) or placebo. A symptom survey was performed on days 0, 1, 2, 3, 5, 7, 10, 20, and 30. Patients were examined on day 14. Children’s conditions were rated as cured, improved, or failed according to scoring rules.

RESULTS: Two thousand one hundred thirty-five children with respiratory complaints were screened for enrollment; 139 (6.5%) had ABS. Fifty-eight patients were enrolled, and 56 were randomly assigned. The mean age was 66 ± 30 months. Fifty (89%) patients presented with persistent symptoms, and 6 (11%) presented with nonpersistent symptoms. In 24 (43%) children, the illness was classified as mild, whereas in the remaining 32 (57%) children it was severe. Of the 28 children who received the antibiotic, 14 (50%) were cured, 4 (14%) were improved, 4 (14%) experienced treatment failure, and 6 (21%) withdrew. Of the 28 children who received placebo, 4 (14%) were cured, 5 (18%) improved, and 19 (68%) experienced treatment failure. Children receiving the antibiotic were more likely to be cured (50% vs 14%) and less likely to have treatment failure (14% vs 68%) than children receiving the placebo.

CONCLUSIONS: ABS is a common complication of viral upper respiratory infections. Amoxicillin/potassium clavulanate results in significantly more cures and fewer failures than placebo, according to parental report of time to resolution of clinical symptoms.

 

Treatment of Kawasaki Disease

Treatment of Kawasaki Disease: Analysis of 27 US Pediatric Hospitals From
2001 to 2006
Mary Beth F. Son, Kimberlee Gauvreau, Lin Ma, Annette L. Baker, Robert P.
Sundel, David R. Fulton, and Jane W. Newburger
Pediatrics 2009;124 1-8

OBJECTIVES: We sought to analyze trends in admissions and to describe therapies used for acute Kawasaki disease over a 6-year period.

METHODS: The Pediatric Health Information System provides patient data including demographic variables, International Classification of Diseases, Ninth Revision codes, and services billed to patients. Patient identifiers enable tracking of medication use in and across multiple admissions within a center. We analyzed data for patients with (1) a diagnosis code for Kawasaki disease, (2) intravenously administered immunoglobulin treatment during hospitalization, and (3) discharge between January 1, 2001, and December 30, 2006, from 27 hospitals contributing complete data over the study period.

RESULTS: During the study period, 5197 Kawasaki disease admissions were identified for 4811 patients; numbers increased 32.6% from 2001 (n = 678) to 2006 (n = 899). Retreatment with intravenous immunoglobulin was administered to 712 patients (14.8%) over the study period. Other antiinflammatory therapies included intravenously administered methylprednisolone (5.8%), orally administered prednisone (2.8%), and infliximab (1%). Use of infliximab steadily increased from 0.0% (0 of 678 patients) in 2001 to 2.3% (21 of 899 patients) in 2006. Coronary artery aneurysms were coded for 3.3% of patients. Male patients, patients <1 year of age, and Hispanic patients were significantly more likely to have coding for coronary artery aneurysms.

CONCLUSIONS: Our report provides the first large multicenter description of agents used in the treatment of intravenously administered immunoglobulin-resistant Kawasaki disease in the United States. Trends include increased numbers of admissions attributable to Kawasaki disease and increased usage of infliximab.

Chest compressions & Kids

Estimation of Optimal CPR Chest Compression Depth in Children by Using
Computer Tomography
Matthew S. Braga, Troy E. Dominguez, Avrum N. Pollock, Dana Niles, Andrew
Meyer, Helge Myklebust, Jon Nysaether, and Vinay Nadkarni
Pediatrics 2009;124 e69-e74

OBJECTIVE: Pediatric consensus-driven cardiopulmonary resuscitation guidelines target chest compression (CC) depths of one third to one half anterior-posterior (AP) chest depth. Estimates for this target as assessed by computed tomography (CT) measurements of internal and external AP chest dimensions could direct future pediatric cardiopulmonary resuscitation guidelines.

METHODS: A total of 280 consecutive chest CT scans in permuted blocks of 20 for each of 14 age divisions between 0 and 8 years were reconstructed and analyzed. External and internal AP depths were measured at midsternum, and residual chest depth was calculated at simulated one-third and one-half AP compressions.

RESULTS: After a simulated compression calculation, one-half external AP depth CC would result in residual internal depth of <10 mm for 94% (263 of 280) of children 3 months to 8 years. For a one-third external AP CC, only 0.4% (1 of 280) of children 3 months to 8 years had a calculated residual internal chest depth <10 mm.

CONCLUSIONS: By using CT reconstruction estimates of chest dimensions across the developmental spectrum from 0 to 8 years of age, we demonstrated that a simulated CC targeting approximately one-third external AP chest depth seems radiographically appropriate for children aged 3 months to 8 years, whereas simulated CC targeting approximately one-half external AP chest depth seems radiographically to be too deep, resulting in residual internal chest depth of <10 mm for most patients of this age.

Kids’ wheezing: To x-ray and not to x-ray—that is the question

Clinical Predictors of Pneumonia Among Children With Wheezing
Bonnie Mathews, Sonal Shah, Robert H. Cleveland, Edward Y. Lee, Richard G.
Bachur, and Mark I. Neuman
Pediatrics 2009;124 e29-e36

OBJECTIVE: The goal was to identify factors associated with radiographically confirmed pneumonia among children with wheezing in the emergency department (ED) setting.

METHODS: A prospective cohort study was performed with children < 21 years of age who were evaluated in the ED, were found to have wheezing on examination, and had chest radiography performed because of possible pneumonia. Historical features and examination findings were collected by treating physicians before knowledge of the chest radiograph results. Chest radiographs were read independently by 2 blinded radiologists.

RESULTS: A total of 526 patients met the inclusion criteria; the median age was 1.9 years (interquartile range: 0.7–4.5 years), and 36% were hospitalized. A history of wheezing was present for 247 patients (47%). Twenty-six patients (4.9% [95% confidence interval [CI]: 3.3–7.3]) had radiographic pneumonia. History of fever at home (positive likelihood ratio [LR]: 1.39 [95% CI: 1.13–1.70]), history of abdominal pain (positive LR: 2.85 [95% CI: 1.08–7.54]), triage temperature of ≥38°C (positive LR: 2.03 [95% CI: 1.34–3.07]), maximal temperature in the ED of ≥38°C (positive LR: 1.92 [95% CI: 1.48–2.49]), and triage oxygen saturation of <92% (positive LR: 3.06 [95% CI: 1.15–8.16]) were associated with increased risk of pneumonia. Among afebrile children (temperature of <38°C) with wheezing, the rate of pneumonia was very low (2.2% [95% CI: 1.0–4.7]).

CONCLUSIONS: Radiographic pneumonia among children with wheezing is uncommon. Historical and clinical factors may be used to determine the need for chest radiography for wheezing children. The routine use of chest radiography for children with wheezing but without fever should be discouraged.

Kids & headaches

Headache in Young Children in the Emergency Department: Use of Computed
Tomography
Tarannum M. Lateef, Mandeep Grewal, William McClintock, James Chamberlain,
Himanshu Kaulas, and Karin B. Nelson
Pediatrics 2009;124 e12-e17

Headache in Young Children in the Emergency Department: Use of Computed Tomography

Tarannum M. Lateef, MDa, Mandeep Grewal, BSa, William McClintock, MDa, James Chamberlain, MDb, Himanshu Kaulas, MBBSa and Karin B. Nelson, MDa,c

 

Departments of a Neurology
b Emergency Medicine, Children’s National Medical Center and George Washington University School of Medicine, Washington, DC
c National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland

OBJECTIVE: The goal was to determine whether computed tomographic (CT) scans led to better acute care of young children with headache presenting the emergency department (ED).

METHODS: We examined the records of 364 children 2 to 5 years of age who presented with headache to a large urban ED between July 1, 2003, and June 30, 2006. By reviewing initial history and examination findings, we first identified patients with secondary headaches (ie, with readily identifiable explanations such as ventriculoperitoneal shunts, known brain tumors, or acute illnesses, such as viral syndromes, fever, probable meningitis, or trauma). Charts for the remaining patients were reviewed for headache history, neurologic examination findings, laboratory and neuroimaging results, final diagnosis, and disposition.

RESULTS: On the basis of initial history and physical examination results, 306 children (84%) had secondary headaches. For 72% of those children, acute febrile illnesses and viral respiratory syndromes accounted for the headaches. Among the 58 children (16%) who had no recognized central nervous system disease or systemic illness at presentation, 28% had CT scans performed. Of those, 1 scan yielded abnormal results, showing a brainstem glioma; the patient demonstrated abnormal neurologic examination findings on the day of presentation. For 15 (94%) of 16 patients, the CT scans did not contribute to diagnosis or management. For 59% of children with apparently primary headaches, no family history was recorded.

CONCLUSION: For young children presenting to the ED with headache but normal neurologic examination findings and nonworrying history, CT scans seldom lead to diagnosis or contribute to immediate management.

Walkers and Canes can be hazardous to one’s health

47,000 Older Adults Treated in Emergency Departments Annually for Fall Injuries Related to Walkers and Canes

CDC:  http://www.cdc.gov/media/pressrel/2009/r090629.htm

Fractures most common injury; one in three injuries required hospitalization

From 2001 to 2006, an average of 129 Americans ages 65 and older were treated in emergency departments each day—a total of more than 47,000 each year—for injuries from falls that involved walkers and canes, according to a Centers for Disease Control and Prevention study published this month in the Journal of the American Geriatrics Society.

The study, which examined six years of emergency department medical records, found that, for older adults that had falls related to walkers- or canes, most of the injuries involved walkers (87 percent). People were seven times more likely to be injured in a fall with a walker as with a cane. Older women sustained more than three out of four walker-related injuries (78 percent) and two out of three cane-related injuries (66 percent).

“Walking aids are very important in helping many older adults maintain their mobility. However, it′s important to make sure people use these devices safely,” said Judy Stevens, Ph.D., the study′s lead author. “Walkers are often used by frail and vulnerable older adults; people for whom falls, if they occur, can have very serious health consequences.”

Other key findings include:

  • For men and women who used walkers or canes, the chances of sustaining a fall increased with age, with the highest injury rates among those ages 85 and older.
  • Fractures were the most common type of fall injury associated with walkers (38 percent) and canes (40 percent) and about a third of all injuries were to the lower trunk, such as the hip or pelvis.
  • More than half of fall injuries associated with walkers (60 percent) and canes (56 percent) occurred at home.
  • One in three people whose fall involved a walker and more than one in four (28 percent) whose fall involved a cane had to be hospitalized.

The study points out the importance of preventing falls related to walking aids. Some prevention strategies include:

  • Encouraging professionals to spend more time with clients (or patients) fitting walking aids, and;
  • Educating people how to use walkers and canes safely, for example, by having physical therapists provide counseling at health fairs.

Additional studies are needed to better understand fall risk factors for older adults who use walkers and canes, as well as to identify potential design problems and improve the design of walkers.

Falls are the leading cause of nonfatal injury in the United States, and falls among older adults can have especially serious consequences. To help reduce the risk of falling, CDC′s Injury Center recommends that adults ages 65 and older begin a regular exercise program, have their doctors review their medications, have their vision checked, and make their home surroundings safer.

For more information about CDC′s fall prevention efforts among older adults, please link to http://www.cdc.gov/HomeandRecreationalSafety/Falls/index.html.

For information about protecting children from falls, visit http://www.cdc.gov/HomeandRecreationalSafety/Falls/children.html.

For a full copy of the study, please visit the Journal of the American Geriatrics Society at http://www3.interscience.wiley.com/journal/119878233/issue.

WHO: H1N1 Map of the World

http://www.who.int/entity/csr/don/Globalh1n1_20090629.png

1

Flu activity decreased in US

Seasonal Influenza Weekly Report: Influenza Summary Update - CDC – June 26
During week 24 (June 14-20, 2009), influenza activity decreased in the United States, however, there were still higher levels of influenza-like illness than is normal for this time of year.

1

OMNI Postings of 6/29/09

On this date in 1776, Virginia adopts the state constitution and makes Patrick Henry governor.  Well…actually…he was the politicians’ second choice.  The day before, they selected Bruce Wainwright, but they couldn’t locate the chap. Family and friends stated he was out tramping through the Appalachians.  Then it was discovered he was vacationing in the Cherokee Nation enjoying a rendevous with a certain Little Big Butt.

But I digress…..

A panel of experts has recommended to the FDA to approve Bepreve as an anti-itching drug for the “baby blues.”  The final decision may happen in September…typically when eyes stop itching.
http://omniphysicians.com/2009/06/29/bepreve-bepotastine-besilate/

Here’s a case of a kid who was swimming in a lake and caught a weird bacterium.  It’s costing him part of his face.  It’s a rare disease.  Fewer than 150
cases have been reported worldwide since 1927.
http://omniphysicians.com/2009/06/29/chromobacterium-violaceum/

A big cat was let out of the bag this Sunday when it was suggested that the Prez might allow taxation of employee benefits.  Well, I won’t say what I think about this until I hear what Rush wants me to think.
http://omniphysicians.com/2009/06/29/taxing-employee-benefits/

This USA Today article is citing stories about all the accidents Americans are having because they are doing their own repairs.  Because of the economy, instead of calling qualified workers, they are doing the jobs and hurting themselves…even surgeons.  So…where do they go?  You guessed it.  One guy came in with a bullet in his foot.  He wanted to kill his wife, but he couldn’t afford the “boys” from Detroit.  So he tried himself and missed.
http://omniphysicians.com/2009/06/29/its-the-economy-stupid/

Paul R.

Anti-Virals, H1N1, & Pregnancy

Oseltamivir poses little risk in pregnant women treated for influenza H1N1
By MedWire Reporters
23 June 2009
CMAJ 2009; 181: 55–58

MedWire News: It is acceptable for pregnant women requiring treatment for the novel influenza A H1N1 virus to be treated treated with oseltamivir, research shows.

Zanamivir, which is a similar neuraminidase inhibitor, can also be used in pregnant women, although there is less supporting safety data, according to a review by Toshihiro Tanaka (Sick Children’s Hospital, Toronto, Canada) and colleagues in the Canadian Medical Association Journal.

Pregnant women, especially those in the late stages of pregnancy, are at high risk for complications from influenza, including H1N1 strain. A recent government report stated that 15 confirmed and five probable H1N1 infections in the US were in pregnant women.

“Although the novel H1N1 influenza virus may not be as virulent as anticipated, the increased risk of complications during pregnancy should be taken into account when caring for affected patients,” comment Tanaka and colleagues.

The group summarized available safety data on the use of neuraminidase inhibitors for the treatment of the H1N1 influenza in pregnant and breastfeeding women.

Their review suggests that oseltamivir is not a major teratogen for humans.

Although zanamivir may be used, there are fewer data available about its safety in pregnant women, say the researchers.

The group also reviewed use of these medications in lactating women.

“Both oseltamivir and zanamivir are considered to be compatible with breastfeeding,” the group reports. “Continuation of breastfeeding by a woman taking these medications is unlikely to lead to substantial drug exposure by the infant.”

A dose adjustment in breastfeeding mothers is not required, the team recommends. Infants requiring treatment can also be prescribed the drugs, although the dose should be adjusted based on their weight.

In adults, the therapeutic dose of oseltamivir, a prodrug hydrolyzed by the liver, is 75 mg twice daily for 5 days, starting within 48 hours of initial symptoms. The therapeutic dose of zanamivir is 10 mg inhaled twice daily for 5 days and is also started within 48 hours of initial symptoms. For prophylaxis, treatment with both agents is continued for 10 days.

MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a part of Springer Science+Business Media. © Current Medicine Group Ltd; 2009 

Free full text [pdf]

Bepreve [bepotastine besilate]

http://www.forbes.com/feeds/ap/2009/06/26/ap6592794.html

AP, 6/27/09

“A panel of federal experts said Friday an anti-itching drug from eye care company Ista Pharmaceuticals is safe and effective, according to a government spokeswoman.

The unanimous vote from the seven members of the Food and Drug Administration’s opthalmic panel amounts to a recommendation for approval. Although the FDA is not required to follow the group’s advice, it usually does….

A final decision on the drug is expected by September.”